| |
Male (n = 167)
|
Female (n = 107)
|
All (n = 274)
|
|---|
|
No amyloidosis
|
80 (48%)
|
62 (58%)
|
142 (52%)
|
|
TTR mutation
|
22 (28%)
|
31 (50%)
|
53 (37%)
|
|
No TTR mutation
|
58 (72%)
|
31 (50%)
|
89 (63%)
|
|
Amyloidosis
|
87 (52%)
|
45 (42%)
|
132 (48%)
|
|
ATTRv amyloidosis
|
82 (94%)
|
41 (91%)
|
123 (93%)
|
|
Dx before 2006
|
10 (12%)
|
9 (22%)
|
19 (16%)
|
|
ATTRV30M
|
69 (84%)
|
31 (76%)
|
100 (81%)
|
|
Other mutationa
|
3 (4%)
|
1 (2%)
|
4 (3%)
|
|
ATTRwt amyloidosis
|
1 (1%)
|
0 (0%)
|
1 (1%)
|
|
AL amyloidosis
|
4 (5%)
|
3 (7%)
|
7 (5%)
|
|
Localized
|
3 (75%)
|
3 (100%)
|
6 (86%)
|
|
Systemic
|
1 (25%)
|
0 (0%)
|
1 (14%)
|
|
Gelsolin amyloidosis
|
0 (0%)
|
1 (2%)
|
1 (1%)
|
- aH88R, A45S, V122I and A97S; AL, amyloid light chain; ATTRv, variant transthyretin amyloidosis; ATTRV30M, transthyretin amyloidosis caused by the TTR V30M mutation; ATTRwt, wild-type transthyretin amyloidosis; Dx, diagnosis; TTR, transthyretin gene. Percentages are shown as column percentage within each heading/subheading
